Research progress of radiolabeled FAPIs in the tumor targeted diagnosis and therapy
10.3760/cma.j.cn321828-20200421-00162
- VernacularTitle:放射性标记FAPIs在肿瘤靶向诊疗中的研究进展
- Author:
Yili XIANG
1
;
Zhongbao RUAN
;
Jun ZHANG
;
Li ZHU
Author Information
1. 南京中医药大学附属泰州市人民医院核医学科 225300
- Keywords:
Quinolines;
Isotope labeling;
Neoplasms;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2021;41(11):683-688
- CountryChina
- Language:Chinese
-
Abstract:
Cancer-associated fibroblasts (CAFs) are essential parts of tumor stroma. Fibroblast activation protein (FAP), overexpressed in CAFs, is closely related to tumor growth, invasion, metastasis, immunosuppression and prognosis, which is a vital target for tumor targeted diagnosis and therapy. In recent years, a variety of new radiolabeled quinoline-based FAP inhibitors (FAPIs) have been used for tumor targeted diagnostic and therapeutic research. A number of studies have confirmed that radiolabeled FAPIs plays an important role in tumor diagnosis, staging and treatment, which have a good clinical application prospect. This review summarizes the research status of radiolabeled FAPIs and discusses their potential in the accurate diagnosis and therapy of tumors.
